๎
๎ผ
๋ก๊ทธ์ธ
๎
Repare Therapeutics Inc
RPTX2.650USD
0.0000.00%
์ข
๊ฐย 03/30, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
113.91M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Repare Therapeutics Inc ํ์ฌ
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ RPTX
ํ์ฌ ์ด๋ฆRepare Therapeutics Inc
์์ฅ์ผJun 19, 2020
CEOForte (Steve)
์ง์ ์129
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJun 19
์ฃผ์7210 Frederick-Banting, Suite 100
๋์ST-LAURENT
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐCanada
์ฐํธ ๋ฒํธH4S 2A1
์ ํ18574127018
์น์ฌ์ดํธhttps://www.reparerx.com/
์ข
๋ชฉ ์ฝ๋ RPTX
์์ฅ์ผJun 19, 2020
CEOForte (Steve)
Repare Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-100.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
์์ต ๋ถ์
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Jan 6
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Jan 6
FY2025Q3
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ง์ญ๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Switzerland
11.62M
0.00%
United States
0.00
0.00%
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Feb 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Feb 1
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
๊ธฐํ
71.82%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
๊ธฐํ
71.82%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Hedge Fund
13.86%
Investment Advisor/Hedge Fund
11.55%
Investment Advisor
10.04%
Private Equity
7.74%
Research Firm
0.76%
Individual Investor
0.31%
Venture Capital
0.27%
๊ธฐํ
55.47%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Jan 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Jan 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q4
116
24.72M
57.35%
-9.60M
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Blue Owl Capital Holdings LP
3.37M
7.82%
-71.16K
-2.07%
Nov 21, 2025
OrbiMed Advisors, LLC
3.20M
7.42%
-124.40K
-3.74%
Nov 21, 2025
Redmile Group, LLC
1.59M
3.68%
--
--
Sep 30, 2025
MPM Capital Inc.
1.12M
2.6%
--
--
Sep 30, 2025
MPM BioImpact LLC
819.92K
1.9%
--
--
Sep 30, 2025
Renaissance Technologies LLC
724.16K
1.68%
+201.30K
+38.50%
Sep 30, 2025
Citadel Advisors LLC
699.30K
1.62%
-238.19K
-25.41%
Sep 30, 2025
Rangeley Capital LLC
645.88K
1.5%
+290.58K
+81.79%
Sep 30, 2025
Acadian Asset Management LLC
568.30K
1.32%
-112.88K
-16.57%
Sep 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
๋น์จ0%
Avantis US Small Cap Equity ETF
๋น์จ0%
Avantis US Equity ETF
๋น์จ0%
SPDR S&P International Small Cap ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
